Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer

被引：0
|
作者：
Jiang, M. [1 ]
Chai, Y. [1 ]
Liu, J. [2 ]
He, M. [1 ]
Zhang, M. [1 ]
Zhou, S. [1 ]
Xu, B. [3 ]
Li, Q. [2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Med Oncol, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.270
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331P
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [21] Everolimus combination prolongs PFS in HER2-positive advanced breast cancer
    Fuerst, Mark L.
    FORMULARY, 2013, 48 (07) : 238 - 238
  • [22] Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial
    Gianni, L.
    Eiermann, W.
    Semiglazov, V
    Manikhas, G. M.
    Lluch, A.
    Tjulandin, S.
    Feyereislova, A.
    Valagussa, P.
    Baselga, J.
    CANCER RESEARCH, 2009, 69 (02) : 70S - 71S
  • [23] Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
    Semiglazov, V.
    Eiermann, W.
    Manikhas, A.
    Bozok, A.
    Lluch, A.
    Tjulandine, S.
    Feyereislova, A.
    Valagussae, P.
    Baselga, J.
    Gianni, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 169 - 170
  • [24] Loss of androgen receptor after neoadjuvant anti-HER2 therapy in patients with locally advanced HER2-positive breast cancer
    Espinosa Fernandez, Jose Rodrigo
    Sahin, Aysegul A.
    Hess, Kenneth R.
    Ramirez Medina, Raul Gerardo
    Cabrera Galeana, Paula Anel
    Espana Ferrufino, Alejandro Javier
    Esparza Arias, Nereida
    Bargallo Rocha, Juan Enrique
    Garcia Gordillo, Jose Antonio
    Lopez Muniz, Gerardo Emmanuel
    Ueno, Naoto T.
    CANCER RESEARCH, 2020, 80 (04)
  • [25] The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced HER2-positive breast cancer
    Esfahani, K.
    Ferrario, C.
    Le, P.
    Panasci, L.
    CURRENT ONCOLOGY, 2014, 21 (05) : E723 - E727
  • [26] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    BREAST CARE, 2017, 12 (01) : 45 - 47
  • [27] NEW IMMUNOHISTOCHEMICAL MARKERS PREDICTIVE OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY PLUS TRASTUZUMAB IN HER2-POSITIVE LOCALLY ADVANCED BREAST CANCER: A SINGLE CENTER EXPERIENCE
    Faggioni, G.
    Ghiotto, C.
    Orvieto, E.
    Valpione, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 124 - 124
  • [28] ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL
    Ribeiro, I
    Lourenco, O.
    Alves, C.
    Thuresson, P.
    Monteiroa, I
    Batel-Marques, F.
    VALUE IN HEALTH, 2016, 19 (07) : A736 - A737
  • [29] Radiotherapy plus trastuzumab in the treatment of Her2-positive locally advanced breast cancer
    Belokhvostova, A.
    Ragulin, Y.
    ANNALS OF ONCOLOGY, 2015, 26
  • [30] The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.
    Lavasani, S. M.
    Pritchard, K. I.
    Kiss, A.
    Verma, S.
    Wright, F.
    Boileau, J.
    Trudeau, M. E.
    Czarnota, G. J.
    Dent, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345